



Project BASTION „From Basic to Translational Research in Oncology”

Kick-off Meeting International Advisory Board Meeting

Warsaw



November 27th 2012


Magdalena Winiarska





CD20 antigen





BASTION


Anti-CD20 monoclonal antibodies

Antibody	Clinical status	Characteristics	
		Origin	Isotype
Rituximab	approved	chimeric	IgG1
Tositumomab	approved	murine	IgG2a
Ofatumumab	approved	human	IgG1
Ibritumomab	approved	murine	IgG1
Ocrelizumab	phase 3	humanized	IgG1
Veltuzumab	phase 2	humanized	IgG1
Obinutuzumab	phase 2	humanized	IgG1
PRO131921	phase 2	humanized	IgG1
AME-133	phase 2	humanized	IgG1
LFB-R603/EMAB-6	phase 1	chimeric	IgG1









Anti-CD20 mAbs: mechanism of action






Multi-Src family kinase inhibitors down-regulate CD20 and affect R-CDC





Bojarczuk K





BASTION



Prenyl transferases regulate CD20 levels and influence R-CDC



Winiarska et al. J Biol Chem. 2012;287(38):31983-93.








Bortezomib modulates CD20 levels and affects R-CDC



Bil et al. Blood. 2010;115(18):3745-55



HDAC6 inhibitors up-regulate CD20 levels and improve R-CDC




Wanczyk M





Statins impair antitumor effects of rituximab



Winiarska *et al.* PLoS Med. 2008;5(3):e64.





Acknowledgements

Małgorzata Wańczyk, Kamil Bojarczuk, Michał Dwojak, Marta Siernicka, Nina Miązek, Piotr Zapała, Anders Bunes, Małgorzata Firczuk, Radosław Zagożdżon, Agnieszka Zagożdżon, Dominika Nowis, Jakub Golab	Department of Immunology Medical University of Warsaw
Maciej Siński, Ewa Wilczek, Grzegorz Basak, Zbigniew Gaciong, Elżbieta Górska, Maria Wąsik	Medical University of Warsaw
Grzegorz M . Wilczyński	Nencki Institute of Experimental Biology
Wendy J.M. Mackus, Patrick J. Engelberts, Paul W.H.I. Parren	Genmab, Utrecht, The Netherlands
Przemysław Juszczynski	Institute of Hematology, Warsaw
Anna Dąbrowska-Iwanicka	Maria Skłodowska-Curie Memorial Cancer Center
Kazimierz Sułek	Department of Clinical Hematology, Military Medical Institute



QUANTITATIVE EVALUATION OF THE CD59 AND CD20 EXPRESSION

(BD Quantibrite™ PE Beads)

		MFI	Molecules/Cell	% of control
CD59	CON	3.67	619	100.00
	LOW	9.22	1573	254.12
	MEDIUM	38.745	6728	1086.91
	HIGH	115.325	20299	3279.32
	VERY HIGH	216.425	38391	6202.10

